Literature DB >> 16343505

The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain.

José R Banegas1, Onofre Vegazo, Pedro Serrano, Emilio Luengo, Teresa Mantilla, Raúl Fernández, Fernando Civeira.   

Abstract

OBJECTIVE: It is well-known that adequate control of dyslipidemia is low. But little is known about how well physicians perceive the control of their dyslipidemic patients. This study examines physicians' subjective perception of dyslipidemia control, and compares it with control determined objectively with published guidelines.
METHODS: A total of 33,913 patients were studied cross-sectionally in 164 Spanish outpatients' clinics. Of these patients, 5583 were evaluable patients with a documented diagnosis of dyslipidemia. Control of dyslipidemia was evaluated by two methods: the physician's opinion on their patient's lipid levels (adequate control or inadequate control), and the proportion of patients who objectively reach the LDL-cholesterol goals of the National Cholesterol Education Program (NCEP/ATPIII).
RESULTS: Physicians perceived that 44% (95% CI 42.7-45.3%) of their patients had an adequate control of their dyslipidemia, but only 32.8% (95% CI 31.6-34.0%) were objectively controlled. Subjective control hardly changed across the NCEP cardiovascular risk groups, but objective control was lower in the 2372 coronary heart disease patients (15.1%) and in the 1407 moderately high-risk patients (29.6%) than in the 1804 lower risk patients (58.5%). Physicians' perception of control was significantly and independently associated with objective control (P<0.001).
CONCLUSIONS: Physicians overestimate dyslipidemia control in the majority of their patients. Misperception of control by physicians may contribute to the low achievement of objective control.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343505     DOI: 10.1016/j.atherosclerosis.2005.11.011

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  [Diabetes mellitus and cardiovascular risk. Is integrated therapy of type 2 diabetes and cardiovascular risk factors necessary?].

Authors:  Domingo Orozco Beltrán; Carlos de la Sen Fernández; Vicente Gil Guillén; Concepción Carratalá Munuera; Jorge Navarro Pérez
Journal:  Aten Primaria       Date:  2010-09       Impact factor: 1.137

2.  [Durability of the effects of a quality improvement intervention in hypertensive patients on long-term follow-up (CICLO-RISK study)].

Authors:  Manuel Angel Gómez Marcos; Emiliano Rodríguez Sánchez; Emilio Ramos Delgado; Carmen Fernández Alonso; Angel Luis Montejo Gónzalez; Luis García Ortiz
Journal:  Aten Primaria       Date:  2009-05-15       Impact factor: 1.137

3.  The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.

Authors:  Vasilios G Athyros; Thomas D Gossios; Niki Katsiki; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2012-02-29       Impact factor: 3.318

4.  Diabetes screening: a pending issue in hypertense/obese patients.

Authors:  Armina Sepehri; Antonio Palazón-Bru; Vicente Francisco Gil-Guillén; Dolores Ramírez-Prado; Felipe Navarro-Cremades; Ernesto Cortés; María Mercedes Rizo-Baeza
Journal:  PeerJ       Date:  2015-04-23       Impact factor: 2.984

5.  [Dyslipidemia management in patients with high cardiovascular risk in Spain. ALMA study].

Authors:  Xavier Pintó; Ferran Trias Vilagut; Joan Rius Taruella; Esther Mairal Sallán
Journal:  Aten Primaria       Date:  2017-06-12       Impact factor: 1.137

6.  The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG).

Authors:  A Ramjeeth; N Butkow; F J Raal; M Maholwana-Mokgatlhe
Journal:  Cardiovasc J Afr       Date:  2008 Mar-Apr       Impact factor: 1.167

7.  GOAL Canada: Physician Education and Support Can Improve Patient Management.

Authors:  Anatoly Langer; Mary Tan; Shaun G Goodman; Jean Grégoire; Peter J Lin; G B John Mancini; James A Stone; Cheryll Wills; Caroline Spindler; Lawrence A Leiter
Journal:  CJC Open       Date:  2019-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.